Life Science Nation Newsletter  | January 18,  2018  |  Issue 249


  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Jan. 11 - Jan. 17 )
Interested in Early-Stage Medtech and Healthcare IT, Including AI/Big Data Applications
Seeks Emerging, Pre-Clinical Life Science Technologies with Strong Interests in Ophthalmology and Dermatology
Invests in Medtech and Diagnostic Companies Targeting Global Unmet Medical Needs
Provides Funding and Equity Investments to Early-Stage Ultrasound Technologies
In This Issue
News
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

LSN is pleased to announce that RESI on MaRS is on schedule to land in Toronto April 10th, and JLABS and MaRS Discovery District will be the Title Sponsors. The big news here is that this event will be larger from an international perspective than previous RESI on MaRS events. The global early stage life science investor and partnering community has stepped up efforts to source technology assets throughout North America, and Toronto has a trove of up and coming startups across the domains of drugs, devices, diagnostics, and healthcare IT.

LSN has built a compelling group of investors and strategic partners (dubbed "the tribe") that use the RESI conferences as a vehicle to source and vet new technologies. These investors all have a mandate to allocate capital resources in order to fill their portfolios and product pipelines and expand their global channels. LSN has already seen very strong interest from investors based in Asia, Europe and the U.S., who are vying for panel slots at the upcoming conference. RESI's panels will feature investors from Asia-based pharma and strategics, global family offices, venture capital firms, angel syndicates, private equity, corporate venture, foundations and impact funds. The market is heating up for early stage technology, and 2018 looks like it will be a banner year for dynamic global partnerships...

By Chris Cummings, Senior Marketing Manager, LSN

In April 2017, RESI brought over 250 qualified life science investors to the Toronto ecosystem. The investors came from all corners of the globe; large strategic partners flew in from China to join local family offices just down the street from MaRS Discovery District. Over 900 meetings occurred over the course of the day. Taking a closer look at exactly where investors came from and who they met with confirms the global cross-pollination of early stage life science RESI fosters.

RESI, for that day, was able to expand the pool of capital in Toronto beyond Canada's borders. About 50% of the investors who attended the event were from the United States, Europe, or Asia...

By Gregory Mannix, Vice President International Business Development, LSN

Where Health Means Business 
For the second year running, RESI on MaRS will be the centerpiece event of the Toronto Health Innovation Week, taking place from April 9th to 13th, 2018. 30+ events will be taking place that week in the Toronto Region, bringing together key players in the life sciences from Canada and around the globe. Life science entrepreneurs, investors, opinion leaders and many others will converge on the region for an intense week of partnering and discussions. Here are some of the highlights:

RESI on MaRS. April 10th (All day) 
350+ global investors and strategics will meet 350+ early-stage life science companies and quality service providers in the industry's premier partnering event for funding...



Created & Produced by

QuickFire Challenge
I n honor of the Grand Opening of JLABS @ NYC, Johnson & Johnson Innovation has launched a QuickFire Challenge to award up to four new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ NYC community for one year.

This competition will award the person or team(s) who submits the best idea, technology, or solution in the following areas:
  • Consumer healthcare
  • Health technologies
  • Medical devices
  • Therapeutics